S&P 500

6.040,53

-0,50%

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

NLSP

NLS Pharmaceutics (NLSP)

NLS Pharmaceutics Ltd

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NLSP

1 2 3 4 5 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
31/01/2025	13h30	PR Newswire (US)	Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics	NASDAQ:NLSP	NLS Pharmaceutics Ltd
30/01/2025	13h30	PR Newswire (US)	NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting	NASDAQ:NLSP	NLS Pharmaceutics Ltd
28/01/2025	13h30	PR Newswire (US)	NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence	NASDAQ:NLSP	NLS Pharmaceutics Ltd
16/01/2025	15h32	PR Newswire (US)	Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS	NASDAQ:NLSP	NLS Pharmaceutics Ltd
08/01/2025	13h42	PR Newswire (US)	NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Pri	NASDAQ:NLSP	NLS Pharmaceutics Ltd
30/12/2024	13h30	PR Newswire (US)	NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger	NASDAQ:NLSP	NLS Pharmaceutics Ltd
04/12/2024	19h15	PR Newswire (US)	NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market	NASDAQ:NLSP	NLS Pharmaceutics Ltd
27/08/2024	22h01	Edgar (US Regulatory)	Form F-1 - Registration statement for certain foreign private issuers	NASDAQ:NLSP	NLS Pharmaceutics Ltd
26/08/2024	22h40	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
15/08/2024	22h02	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
14/08/2024	22h01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
30/07/2024	22h30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
15/07/2024	15h16	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:NLSP	NLS Pharmaceutics Ltd
11/03/2024	21h01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
23/02/2024	22h00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
12/01/2024	23h03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
29/12/2023	22h30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
22/12/2023	22h02	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
06/12/2023	22h44	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
04/12/2023	22h45	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
04/12/2023	22h00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
01/12/2023	13h35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
16/11/2023	22h05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
25/10/2023	22h30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
25/10/2023	15h02	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
13/09/2023	22h03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
30/08/2023	23h25	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
20/07/2023	22h06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
03/07/2023	19h22	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:NLSP	NLS Pharmaceutics Ltd
14/06/2023	14h38	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:NLSP	NLS Pharmaceutics Ltd